 Xenograft Model Antitumor Assays
"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
| Descriptor ID |
D023041
|
| MeSH Number(s) |
E05.337.550.200.900 E05.624.850
|
| Concept/Terms |
Xenograft Model Antitumor Assays- Xenograft Model Antitumor Assays
- Tumor Xenograft Assay
- Xenograft Antitumor Assays
- Antitumor Assay, Xenograft
- Antitumor Assays, Xenograft
- Assay, Xenograft Antitumor
- Assays, Xenograft Antitumor
- Xenograft Antitumor Assay
- Antitumor Assays, Xenograft Model
|
Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".
Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".
This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 6 | 6 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 0 | 5 | 5 | | 2006 | 1 | 3 | 4 | | 2007 | 0 | 5 | 5 | | 2008 | 3 | 8 | 11 | | 2009 | 1 | 14 | 15 | | 2010 | 1 | 13 | 14 | | 2011 | 2 | 13 | 15 | | 2012 | 2 | 23 | 25 | | 2013 | 2 | 18 | 20 | | 2014 | 0 | 19 | 19 | | 2015 | 2 | 24 | 26 | | 2016 | 3 | 21 | 24 | | 2017 | 2 | 35 | 37 | | 2018 | 2 | 26 | 28 | | 2019 | 1 | 27 | 28 | | 2020 | 1 | 30 | 31 | | 2021 | 1 | 13 | 14 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 2 | 2 | | 2024 | 7 | 18 | 25 | | 2025 | 0 | 28 | 28 | | 2026 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
Sottnik JL, Shackleford MT, Nesiba CS, Richer AL, Fleischmann Z, Swartz JM, Rowland CE, Musick M, Fu R, Myler LR, Opresko PL, Mehrotra S, Sokol ES, Hesselberth JR, Diamond JR, Sikora MJ. Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition. Cancer Res. 2026 Apr 02; 86(7):1605-1621.
-
Lindsay H, Du Y, Qi L, Zhang H, Zhao S, Braun FK, Kogiso M, Stephan C, Alton G, Stein G, Beaton G, Kesari S, Neuhauser S, Stearns T, Chuang J, Jocoy EL, Bult CJ, Teicher B, Smith MA, Li XN. Targeting Pediatric Glioblastomas by Combining OLIG2 Inhibitor CT-179 with Fractionated Radiation in a Panel of Patient-Derived Orthotopic Xenograft Mouse Models. Int J Mol Sci. 2026 Feb 04; 27(3).
-
Dela Cruz FS, Stewart EA, Surdez D, Daley JD, Soragni A, Tomazou EM, Alvarez-Perez J, Feinberg TY, Amatruda JF, Ganapathi SS, Ohm JE, Heske CM, Cohen-Gogo S, Pesic D, Nash JO, Shlien A, Roundhill EA, Burchill SA, Crompton BD, Lawlor ER, Loeb DM, Delattre O, Mora J, Scotlandi K, Reed DR, Grohar PJ, Grünewald TGP, Kovar H, Bailey KM. Advancing Preclinical Biology for Ewing Sarcoma: An International Effort. Mol Cancer Ther. 2026 Jan 02; 25(1):48-70.
-
DeGolier KR, Pham-Danis C, Burciaga SD, Walsh ZH, Brzezinski C, Novak AJ, Leach L, Cimons J, Li W, Zhongyu Z, Dimitrov D, Scott-Browne JP, Kohler ME, Fry TJ. Rational redesign of antigen binding domain improves in vivo efficacy of the CD22-CAR. Mol Ther. 2026 Apr 01; 34(4):2175-2188.
-
Wang D, Ritz C, Luo Y, Suresh A, Pierce A, Veo B, Brunt B, Dahl N, Serkova N, Venkataraman S, Danis E, Kus K, Mazan M, Rzymski T, Vibhakar R. Transcriptional regulation of protein synthesis by mediator kinase represents a therapeutic vulnerability in MYC-driven medulloblastoma. Nat Commun. 2025 Dec 16; 16(1):11152.
-
Corr BR, Woodruff ER, Yamamoto TM, Jordan KR, Danhorn T, Bossard C, Nguyen LL, Chuong EB, Wick L, Young A, Kusumoto S, Orsulic S, Barroilhet L, Bitler BG. SM08502-Mediated ß-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression. Cancer Res Commun. 2025 Dec 01; 5(12):2112-2126.
-
Rankin AW, Pham-Danis C, Novak AJ, Danis E, Fry TJ, Kohler ME. Increased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survival. J Immunother Cancer. 2025 Nov 13; 13(11).
-
Henrich IC, Billingsley MM, Jain K, Mondal S, Quick LN, Young R, Nguyen N, Oliveira AM, Blobel GA, Mitchell MJ, Chou MM. Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma. Mol Cancer Ther. 2025 Nov 03; 24(11):1802-1814.
-
Morton JJ, Ramos SA, Alzofon N, Keysar SB, Armitage LH, Baker AS, Barra JM, Chimed TS, Le PN, Nieto C, Weaver AN, Thomas CM, Miller B, Robinson W, Medina TM, Gao D, Russ HA, Jimeno A. Autologous Thymic Organoids Support Functional T-cell Education and Enhance Antitumor Immunity in Humanized Mice with Melanoma Xenografts. Cancer Res Commun. 2025 Nov 01; 5(11):2053-2065.
-
Lentz RW, Lang J, Pitts TM, Blatchford P, Hu J, Jordan KR, Van Bokhoven A, Bagby SM, Dominguez ATA, Binns CA, Robinson HR, Balmaceda N, Baiyee E, Leal AD, Kim SS, Davis SL, Lieu CH, Wadlow RC, Spencer K, Scott AJ, Boland PM, Hochster HS, Messersmith WA. Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer. Cancer Res Commun. 2025 Nov 01; 5(11):2039-2052.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|